|
BiTe
|
NCT#/publication
|
Route/administration schedule
|
Phase
|
Sample size* [follow-up**]
|
Median lines of prior therapy
|
ORR% [CR%]
|
CRS [grade ≥ 3]
|
Neurotoxicity [grade ≥ 3]
|
|---|
|
Blinatumomab
|
NCT00274742 [95, 96]
|
IV continuous infusion over 4 or 8 weeks
|
I
|
24 [5.2]
|
3
|
71.1a [42.8]
|
NP [NP]
|
71 [22]
|
|
Mosunetuzumab
|
NCT02500407 [97]
|
IV once every 21 days
|
I/Ib
|
23 [NP]
|
3
|
NP [NP]
|
28.9 [1.4]
|
43.7 [3.2]
|
|
REGN1979
|
NCT03888105 [98]
|
IV weekly for 12 weeks, then every 2 weeks for 24 weeks
|
I
|
6 [NP]
|
3
|
NP [NP]
|
57 [7.2]
|
NP [3.1]
|
|
GEN3013
|
NCT03625037 [99]
|
Subcutaneous weekly: cycle 1–2; every 2 weeks cycle 3-6; every 28 days thereafter
|
I/II
|
NP
|
3
|
NP [NP]
|
50 [0]
|
0 [0]
|
- Abbreviations: NR not reached, NP not presented, ORR overall response rate, CR complete response, PFS progression-free survival, CRS cytokine release syndrome
- aResponse rate at the target dose of ≥ 60 ug/m2/day (n = 7 MCL patients)
- *The sample size denotes only MCL patients
- **f/up in months
